Tag Archives: Jeff Legos

Breakthrough: Lutathera Shows Significant Progress in Advanced Neuroendocrine Tumor Therapy

(IN BRIEF) Novartis has announced successful results from its Phase III NETTER-2 trial involving Lutathera, a treatment for neuroendocrine tumors (NETs). When used as a first-line treatment in combination with long-acting octreotide, Lutathera significantly improved progression-free survival in patients with … Read the full press release